ORIC Pharmaceuticals (NASDAQ:ORIC) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of ORIC Pharmaceuticals (NASDAQ:ORICFree Report) in a research report released on Thursday morning, Benzinga reports.

Several other analysts have also commented on the stock. HC Wainwright raised their price objective on shares of ORIC Pharmaceuticals from $15.00 to $21.00 and gave the stock a buy rating in a report on Thursday, March 21st. Wedbush raised their price objective on shares of ORIC Pharmaceuticals from $12.00 to $20.00 and gave the stock an outperform rating in a report on Friday, March 1st. Citigroup lowered their price objective on shares of ORIC Pharmaceuticals from $15.00 to $14.00 and set a buy rating for the company in a report on Tuesday, May 7th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of ORIC Pharmaceuticals from $19.00 to $18.00 and set an overweight rating for the company in a report on Wednesday, March 27th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of Buy and an average price target of $20.00.

Check Out Our Latest Report on ORIC

ORIC Pharmaceuticals Trading Up 3.1 %

Shares of NASDAQ:ORIC opened at $7.23 on Thursday. The company has a market cap of $487.45 million, a price-to-earnings ratio of -4.02 and a beta of 1.18. The company has a 50-day moving average price of $8.71 and a 200-day moving average price of $10.32. ORIC Pharmaceuticals has a 12 month low of $5.27 and a 12 month high of $16.65.

ORIC Pharmaceuticals (NASDAQ:ORICGet Free Report) last issued its quarterly earnings data on Monday, May 6th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.07. As a group, research analysts forecast that ORIC Pharmaceuticals will post -1.68 EPS for the current fiscal year.

Hedge Funds Weigh In On ORIC Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Alkeon Capital Management LLC increased its stake in shares of ORIC Pharmaceuticals by 16.8% during the third quarter. Alkeon Capital Management LLC now owns 3,479,289 shares of the company’s stock valued at $21,050,000 after purchasing an additional 500,000 shares in the last quarter. Euclidean Capital LLC increased its position in shares of ORIC Pharmaceuticals by 32.4% during the third quarter. Euclidean Capital LLC now owns 989,410 shares of the company’s stock valued at $5,986,000 after acquiring an additional 241,860 shares in the last quarter. Strs Ohio bought a new stake in shares of ORIC Pharmaceuticals during the fourth quarter valued at approximately $72,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of ORIC Pharmaceuticals during the fourth quarter valued at approximately $58,000. Finally, AJOVista LLC bought a new stake in shares of ORIC Pharmaceuticals during the fourth quarter valued at approximately $40,000. Institutional investors own 95.05% of the company’s stock.

ORIC Pharmaceuticals Company Profile

(Get Free Report)

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

Recommended Stories

Analyst Recommendations for ORIC Pharmaceuticals (NASDAQ:ORIC)

Receive News & Ratings for ORIC Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORIC Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.